ID

45729

Description

Principal Investigator: Edythe London, Ph.D, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA MeSH: Substance-Related Disorders,Methamphetamine,Sex,Ethnic Groups https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001197 The Neural Systems, Inhibitory Control, and Methamphetamine Dependence study started in 2011 and is currently finishing data collection for its last participants. The study included methamphetamine abusing individuals and healthy control participants aged 18-55 years. Participants who qualified over the telephone were scheduled to visit the London Laboratory at the UCLA Semel Institute for Neuroscience and Human Behavior for the In-Person Screening Phase. The screening procedures, usually scheduled over two visits, determined if participants were eligible to complete the subsequent study visits. Both groups completed identical screening procedures, with the exception of more in-depth drug use questions for the methamphetamine users. After providing written consent, participants completed questionnaires about their mood, medical, psychiatric and drug use history, personality and life experiences. They also provided a urine sample to determine what drugs they recently used and a breath sample to determine the carbon monoxide levels in their system. The drug screen tested for recent methamphetamine, cocaine, opiates/opioids, benzodiazepines, THC and other amphetamines. Methamphetamine participants needed to test positive for methamphetamine at admission. If methamphetamine participants tested positive for any drugs other than methamphetamine or marijuana, and if healthy control participants tested positive for any drugs other than marijuana, they were excluded from the study. Additionally, the urine samples of female participants were tested for pregnancy; pregnant females were also excluded. If no exclusionary criteria were met during the first screening visit, participants completed a second screening visit to ensure they were mentally and physically healthy enough to participate. The second screening visit included a psychiatric diagnostic interview (DSM-IV (SCID-I) for first 500 participants and the MINI International Neuropsychiatric Interview M.I.N.I for the last 50 participants). Additionally, laboratory tests and procedures were completed by the UCLA General Clinical Research Center and interpreted by a study physician. Laboratory tests included vital signs (heart rate--BPM, blood pressure, and respirations), an electrocardiogram (ECG) to record the electrical activity of the heart, and an 18-cc blood sample to perform laboratory tests which included a complete chemistry and metabolic panel, hepatic panel, Hepatitis-C tests, and HIV test. The laboratory tests from this blood sample ensured that participants' liver and kidneys were functioning normally, and that their standard blood counts (red cell, white cell, and salts) were also normal. If a Hepatitis-C (HCV) or HIV test was positive, participants were not allowed to continue in the study and their results were reported to the California State Health Department. Participants deemed eligible to continue in the methamphetamine group participated on an outpatient basis or were admitted to the UCLA Medical Center to participate on an inpatient basis for up to 10 days. Typically, detectable levels of methamphetamine in urinalysis remain for 2-3 days, therefore inpatient days 0-3 served as a "washout period" and the methamphetamine abusing inpatient participants provided daily urine samples to test for recent drug use and pregnancy (female participants only). Outpatient participants were also required to remain abstinent from all drugs except nicotine and marijuana for at least 4 days prior to study sessions. Self-reported abstinence for outpatients was verified by urine toxicology and saliva screening at every visit to UCLA before completion of study procedures. Neurocognitive assessments, about three hours each, typically took place on two separate days. The purpose of the neurocognitive sessions were to assess participants' intellectual and neurocognitive functioning. On either the same day as the neurocognitive testing or on separate days, both methamphetamine abusers and healthy controls were administered a structural MRI to collect information on brain structure.

Link

dbGaP-study=phs001197

Keywords

Versions (1)
  1. 5/26/23 5/26/23 - Chiara Middel
Copyright Holder

Edythe London, Ph.D, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA

Uploaded on

May 26, 2023

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

No comments

In order to download data models you must be logged in. Please log in or register for free.

dbGaP phs001197 Neural Systems, Inhibitory Control, and Methamphetamine Dependence

English

Eligibility Criteria

6 forms  
Inclusion and exclusion criteria
Description

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Participants (18-55 years of age) completed a screening visit to ensure that they met criteria for mental and physical health. A physical examination and lab tests were done. The Structured Clinical Inventory for DSM-IV (SCID-I) was used to determine psychiatric diagnoses for the first 500 participants. The MINI International Neuropsychiatric Interview M.I.N.I was used to determine psychiatric diagnoses for the last 50 participants.
Description

Elig.phs001197.v1.p1.1

Data type

boolean

Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C0220908
UMLS CUI [1,3]
C0545082
UMLS CUI [1,4]
C0243161
UMLS CUI [1,5]
C1550543
UMLS CUI [1,6]
C0025353
UMLS CUI [1,7]
C3874265
UMLS CUI [2,1]
C0031809
UMLS CUI [2,2]
C0022885
UMLS CUI [3,1]
C0004936
UMLS CUI [3,2]
C0521095
UMLS CUI [3,3]
C0935589
UMLS CUI [3,4]
C0220952
UMLS CUI [4,1]
C0004936
UMLS CUI [4,2]
C0521095
UMLS CUI [4,3]
C4505426
Exclusion Criteria:
Description

Elig.phs001197.v1.p1.2

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
Psychiatric Disease: Current diagnosis of an Axis I disorder (according to DSM-IV criteria), except for the following:
Description

Elig.phs001197.v1.p1.3

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0521116
UMLS CUI [1,3]
C0270287
UMLS CUI [1,4]
C0220952
UMLS CUI [1,5]
C1705847
Current Stimulant (Meth) Dependence or Abuse (Meth group only)
Description

Elig.phs001197.v1.p1.4

Data type

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0304402
UMLS CUI [1,3]
C0038580
UMLS CUI [1,4]
C0038586
Current Marijuana Dependence or Abuse (both groups)
Description

Elig.phs001197.v1.p1.5

Data type

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0024808
UMLS CUI [1,3]
C0038580
UMLS CUI [1,4]
C0038586
Current Nicotine Dependence (both groups)
Description

Elig.phs001197.v1.p1.6

Data type

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0028043
Current Mood Disorder due to substance use
Description

Elig.phs001197.v1.p1.7

Data type

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0525045
UMLS CUI [1,3]
C0678226
UMLS CUI [1,4]
C0038586
Current Anxiety Disorder due to substance use
Description

Elig.phs001197.v1.p1.8

Data type

boolean

Alias
UMLS CUI [1,1]
C0521116
UMLS CUI [1,2]
C0003469
UMLS CUI [1,3]
C0678226
UMLS CUI [1,4]
C0038586
Drug Use History-Meth abusers must:
Description

Elig.phs001197.v1.p1.9

Data type

boolean

Alias
UMLS CUI [1,1]
C2239127
UMLS CUI [1,2]
C0338666
UMLS CUI [1,3]
C0025611
Meet DSM-IV criteria for current Meth Dependence or Abuse
Description

Elig.phs001197.v1.p1.10

Data type

boolean

Alias
UMLS CUI [1,1]
C1550543
UMLS CUI [1,2]
C0220952
UMLS CUI [1,3]
C0243161
UMLS CUI [1,4]
C0521116
UMLS CUI [1,5]
C0025611
UMLS CUI [1,6]
C0038586
UMLS CUI [1,7]
C0038580
Test positive on day of screening for Meth by urine sample Medications and Substances-Evidence of current use of psychotropic medications or substances other than:
Description

Elig.phs001197.v1.p1.11

Data type

boolean

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0025611
UMLS CUI [1,3]
C2711519
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0439861
UMLS CUI [2,3]
C3887511
UMLS CUI [2,4]
C0521116
UMLS CUI [2,5]
C1524063
UMLS CUI [2,6]
C0033978
UMLS CUI [2,7]
C1705847
Light use of marijuana (both groups)
Description

Elig.phs001197.v1.p1.12

Data type

boolean

Alias
UMLS CUI [1,1]
C1881376
UMLS CUI [1,2]
C1524063
UMLS CUI [1,3]
C0024808
Light use of alcohol (both groups)
Description

Elig.phs001197.v1.p1.13

Data type

boolean

Alias
UMLS CUI [1,1]
C1881376
UMLS CUI [1,2]
C0001948
Nicotine Note: "Light use" defined by qualification for abuse but not dependence. Tobacco (cigarette) consumption is matched between groups to equalize possibly confounding effects of nicotine on cerebral blood flow, which may affect hemodynamic changes measured by fMRI.
Description

Elig.phs001197.v1.p1.14

Data type

boolean

Alias
UMLS CUI [1,1]
C1704788
UMLS CUI [1,2]
C1881376
UMLS CUI [1,3]
C1524063
UMLS CUI [1,4]
C0028040
UMLS CUI [2,1]
C1704788
UMLS CUI [2,2]
C1709790
UMLS CUI [2,3]
C0038586
UMLS CUI [2,4]
C1298908
UMLS CUI [2,5]
C1709790
UMLS CUI [2,6]
C0038580
UMLS CUI [3,1]
C0543414
UMLS CUI [3,2]
C0150103
UMLS CUI [3,3]
C0441833
UMLS CUI [3,4]
C2828389
UMLS CUI [3,5]
C4759729
CNS Disease-Including:
Description

Elig.phs001197.v1.p1.15

Data type

boolean

Alias
UMLS CUI [1,1]
C0007682
Structural brain abnormalities (e.g., neoplasms, subarachnoid cysts)
Description

Elig.phs001197.v1.p1.16

Data type

boolean

Alias
UMLS CUI [1,1]
C0851391
Cerebrovascular disease
Description

Elig.phs001197.v1.p1.17

Data type

boolean

Alias
UMLS CUI [1,1]
C0007820
Infectious disease (e.g., abscess)
Description

Elig.phs001197.v1.p1.18

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
History of other neurological disease, including stroke or head trauma (defined as loss of consciousness >30 min or requiring hospitalization)
Description

Elig.phs001197.v1.p1.19

Data type

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0027765
UMLS CUI [1,3]
C0559159
UMLS CUI [1,4]
C0018674
Cardiovascular Disease:
Description

Elig.phs001197.v1.p1.20

Data type

boolean

Alias
UMLS CUI [1,1]
C0007222
Advanced coronary artery disease, endocarditis, or other cardia disease likely to result in cerebral embolism
Description

Elig.phs001197.v1.p1.21

Data type

boolean

Alias
UMLS CUI [1,1]
C0679246
UMLS CUI [1,2]
C1956346
UMLS CUI [1,3]
C0014118
UMLS CUI [1,4]
C0018799
UMLS CUI [1,5]
C1444708
UMLS CUI [1,6]
C1274040
UMLS CUI [1,7]
C0007780
Any participant that exhibits evidence of left ventricular hypertrophy will be evaluated for a history of hypertension, and will be excluded from participation if positive for hypertension
Description

Elig.phs001197.v1.p1.22

Data type

boolean

Alias
UMLS CUI [1,1]
C0679646
UMLS CUI [1,2]
C3887511
UMLS CUI [1,3]
C0149721
UMLS CUI [1,4]
C0679830
UMLS CUI [1,5]
C0262926
UMLS CUI [1,6]
C0020538
UMLS CUI [2,1]
C0680251
UMLS CUI [2,2]
C0020538
Any participant that reports cardiac symptoms such as chest pain, presyncope and/or syncope with meth use
Description

Elig.phs001197.v1.p1.23

Data type

boolean

Alias
UMLS CUI [1,1]
C0679646
UMLS CUI [1,2]
C0741933
UMLS CUI [1,3]
C0008031
UMLS CUI [1,4]
C0700200
UMLS CUI [1,5]
C0039070
UMLS CUI [1,6]
C1524063
UMLS CUI [1,7]
C0025611
Pulmonary Disease:
Description

Elig.phs001197.v1.p1.24

Data type

boolean

Alias
UMLS CUI [1,1]
C0024115
Significant obstructive pulmonary disease
Description

Elig.phs001197.v1.p1.25

Data type

boolean

Alias
UMLS CUI [1,1]
C0750502
UMLS CUI [1,2]
C0600260
Self-reported active tuberculosis
Description

Elig.phs001197.v1.p1.26

Data type

boolean

Alias
UMLS CUI [1,1]
C2700446
UMLS CUI [1,2]
C0151332
Systemic Disease:
Description

Elig.phs001197.v1.p1.27

Data type

boolean

Alias
UMLS CUI [1,1]
C0442893
Endocrinopathies
Description

Elig.phs001197.v1.p1.28

Data type

boolean

Alias
UMLS CUI [1,1]
C0014130
Renal or hepatic failure
Description

Elig.phs001197.v1.p1.29

Data type

boolean

Alias
UMLS CUI [1,1]
C0035078
UMLS CUI [1,2]
C0085605
Autoimmune disease involving the CNS
Description

Elig.phs001197.v1.p1.30

Data type

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C1314939
UMLS CUI [1,3]
C3714787
Pregnancy:
Description

Elig.phs001197.v1.p1.31

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
Pregnancy, possible pregnancy, or failure to indicate the use of reliable birth control precautions. Note: We administered a pregnancy test to each female participant before starting each of the testing days. Participants must agree to use an effective form of birth control throughout the study. The only acceptable methods of birth control are: 1) oral contraceptive; 2) Depo-Provera injection; 3) intrauterine device; 4) diaphragm with contraceptive jelly; 5) condom with contraceptive jelly, foam, or sponge; 6) tubal ligation or hysterectomy; 7) abstinence from heterosexual intercourse.
Description

Elig.phs001197.v1.p1.32

Data type

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0425965
UMLS CUI [1,3]
C0680095
UMLS CUI [1,4]
C1524063
UMLS CUI [1,5]
C0700589
UMLS CUI [2,1]
C0032976
UMLS CUI [2,2]
C0332152
UMLS CUI [2,3]
C0011008
UMLS CUI [2,4]
C0039593
UMLS CUI [2,5]
C0545082
UMLS CUI [3,1]
C1879533
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C0009905
UMLS CUI [3,4]
C0582269
UMLS CUI [3,5]
C0021900
UMLS CUI [3,6]
C0042241
UMLS CUI [3,7]
C0087145
UMLS CUI [3,8]
C0009653
UMLS CUI [3,9]
C0183461
UMLS CUI [3,10]
C0020699
UMLS CUI [3,11]
C0520483
UMLS CUI [3,12]
C0036899
HIV:
Description

Elig.phs001197.v1.p1.33

Data type

boolean

Alias
UMLS CUI [1,1]
C0019682
HIV-seropositive will be excluded because HIV infection and the development of AIDS produce alterations in brain activity that are dependent on the stage of AIDS. Such effects on brain activity would confound the results of this study.
Description

Elig.phs001197.v1.p1.34

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0019699
UMLS CUI [1,3]
C0001175
Severe Hepatic Impairment:
Description

Elig.phs001197.v1.p1.35

Data type

boolean

Alias
UMLS CUI [1,1]
C0948807
UMLS CUI [1,2]
C0205082
Participants who have severe hepatic impairment, as assessed by blood tests and/or medical history, will be excluded from participation in order to reduce the risk of an adverse effect due to the administration of medication.
Description

Elig.phs001197.v1.p1.36

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0948807
UMLS CUI [1,4]
C1516048
UMLS CUI [1,5]
C0022885
UMLS CUI [1,6]
C0262926
UMLS CUI [1,7]
C0392756
UMLS CUI [1,8]
C0035647
UMLS CUI [1,9]
C0877248
Only for MRI Procedures:
Description

Elig.phs001197.v1.p1.37

Data type

boolean

Alias
UMLS CUI [1,1]
C0024485
We excluded any participant whose body contains a ferromagnetic implanted device that might produce a safety hazard during fMRI. We followed guidelines found in the manual, Magnetic Resonance: Bioeffects, Safety, and Patient Management, supplemented by the current information published on the International MR Safety Website: http://www.mrisafety.com/safety_info.asp
Description

Elig.phs001197.v1.p1.38

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C3693688
UMLS CUI [1,3]
C2911688
UMLS CUI [1,4]
C0347984
UMLS CUI [1,5]
C0376335
Language:
Description

Elig.phs001197.v1.p1.39

Data type

boolean

Alias
UMLS CUI [1,1]
C0023008
Lack of fluency in English. If a participant is not a fluent English speaker, the language barrier would interfere with performance of psychological tests and completing questionnaires used in the study. The consent form, all questionnaires and instructions are given in English.
Description

Elig.phs001197.v1.p1.40

Data type

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C0564215
UMLS CUI [1,3]
C0376245
UMLS CUI [2,1]
C0237167
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0597198
UMLS CUI [2,4]
C0033905
UMLS CUI [2,5]
C0034394
UMLS CUI [3,1]
C0034394
UMLS CUI [3,2]
C0021430
UMLS CUI [3,3]
C1442085
UMLS CUI [3,4]
C0376245
Neurological:
Description

Elig.phs001197.v1.p1.41

Data type

boolean

Alias
UMLS CUI [1,1]
C0746866
Neurological status that is not within normal limits as determined by a physician and as indicated in self-reports.
Description

Elig.phs001197.v1.p1.42

Data type

boolean

Alias
UMLS CUI [1,1]
C0746866
UMLS CUI [1,2]
C0205161
UMLS CUI [1,3]
C0521095
UMLS CUI [1,4]
C0031831
UMLS CUI [1,5]
C2700446
Radiation Exposure: Participated in any other research study involving exposure to ionizing radiation in the past year, relating to study visit date, if the total cumulative exposure from the past research studies and the current research study exceeded the limits described by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must have remained below 5 rems, and the cumulated dose to all other organs must have remained below 15 rems.
Description

Elig.phs001197.v1.p1.43

Data type

boolean

Alias
UMLS CUI [1,1]
C0015333
UMLS CUI [1,2]
C0679823
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C0008972
UMLS CUI [1,5]
C0479513
UMLS CUI [1,6]
C4086728
UMLS CUI [1,7]
C2986497
UMLS CUI [1,8]
C0015333
UMLS CUI [1,9]
C3846158
UMLS CUI [1,10]
C0150269
UMLS CUI [1,11]
C0678257
UMLS CUI [1,12]
C0041714
UMLS CUI [2,1]
C2986497
UMLS CUI [2,2]
C0370231
UMLS CUI [2,3]
C1328851
UMLS CUI [2,4]
C0023317
UMLS CUI [2,5]
C0018067
UMLS CUI [2,6]
C0439092
UMLS CUI [2,7]
C3846158
UMLS CUI [3,1]
C2986497
UMLS CUI [3,2]
C0205394
UMLS CUI [3,3]
C0178784
UMLS CUI [3,4]
C0439092
UMLS CUI [3,5]
C3846158
Radiation Exposure: Participated in any other research study involving exposure to ionizing radiation in the past year, relating to study visit date, if the total cumulative exposure from the past research studies and the current research study exceeded the limits described by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must have remained below 5 rems, and the cumulated dose to all other organs must have remained below 15 rems.
Description

Elig.phs001197.v1.p1.44

Data type

boolean

Alias
UMLS CUI [1,1]
C0015333
UMLS CUI [1,2]
C0679823
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C0008972
UMLS CUI [1,5]
C0479513
UMLS CUI [1,6]
C2986497
UMLS CUI [1,7]
C0015333
UMLS CUI [1,8]
C3846158
UMLS CUI [1,9]
C0150269
UMLS CUI [1,10]
C0678257
UMLS CUI [1,11]
C0041714
UMLS CUI [2,1]
C2986497
UMLS CUI [2,2]
C0370231
UMLS CUI [2,3]
C1328851
UMLS CUI [2,4]
C0023317
UMLS CUI [2,5]
C0439092
UMLS CUI [2,6]
C3846158
UMLS CUI [3,1]
C2986497
UMLS CUI [3,2]
C0205394
UMLS CUI [3,3]
C0178784
UMLS CUI [3,4]
C0439092
UMLS CUI [3,5]
C3846158
Back to the top of the page

Similar models

Eligibility Criteria

6 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.1
Item
Participants (18-55 years of age) completed a screening visit to ensure that they met criteria for mental and physical health. A physical examination and lab tests were done. The Structured Clinical Inventory for DSM-IV (SCID-I) was used to determine psychiatric diagnoses for the first 500 participants. The MINI International Neuropsychiatric Interview M.I.N.I was used to determine psychiatric diagnoses for the last 50 participants.
boolean
C0001779 (UMLS CUI [1,1])
C0220908 (UMLS CUI [1,2])
C0545082 (UMLS CUI [1,3])
C0243161 (UMLS CUI [1,4])
C1550543 (UMLS CUI [1,5])
C0025353 (UMLS CUI [1,6])
C3874265 (UMLS CUI [1,7])
C0031809 (UMLS CUI [2,1])
C0022885 (UMLS CUI [2,2])
C0004936 (UMLS CUI [3,1])
C0521095 (UMLS CUI [3,2])
C0935589 (UMLS CUI [3,3])
C0220952 (UMLS CUI [3,4])
C0004936 (UMLS CUI [4,1])
C0521095 (UMLS CUI [4,2])
C4505426 (UMLS CUI [4,3])
Elig.phs001197.v1.p1.2
Item
Exclusion Criteria:
boolean
C0680251 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.3
Item
Psychiatric Disease: Current diagnosis of an Axis I disorder (according to DSM-IV criteria), except for the following:
boolean
C0004936 (UMLS CUI [1,1])
C0521116 (UMLS CUI [1,2])
C0270287 (UMLS CUI [1,3])
C0220952 (UMLS CUI [1,4])
C1705847 (UMLS CUI [1,5])
Elig.phs001197.v1.p1.4
Item
Current Stimulant (Meth) Dependence or Abuse (Meth group only)
boolean
C0521116 (UMLS CUI [1,1])
C0304402 (UMLS CUI [1,2])
C0038580 (UMLS CUI [1,3])
C0038586 (UMLS CUI [1,4])
Elig.phs001197.v1.p1.5
Item
Current Marijuana Dependence or Abuse (both groups)
boolean
C0521116 (UMLS CUI [1,1])
C0024808 (UMLS CUI [1,2])
C0038580 (UMLS CUI [1,3])
C0038586 (UMLS CUI [1,4])
Elig.phs001197.v1.p1.6
Item
Current Nicotine Dependence (both groups)
boolean
C0521116 (UMLS CUI [1,1])
C0028043 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.7
Item
Current Mood Disorder due to substance use
boolean
C0521116 (UMLS CUI [1,1])
C0525045 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0038586 (UMLS CUI [1,4])
Elig.phs001197.v1.p1.8
Item
Current Anxiety Disorder due to substance use
boolean
C0521116 (UMLS CUI [1,1])
C0003469 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0038586 (UMLS CUI [1,4])
Elig.phs001197.v1.p1.9
Item
Drug Use History-Meth abusers must:
boolean
C2239127 (UMLS CUI [1,1])
C0338666 (UMLS CUI [1,2])
C0025611 (UMLS CUI [1,3])
Elig.phs001197.v1.p1.10
Item
Meet DSM-IV criteria for current Meth Dependence or Abuse
boolean
C1550543 (UMLS CUI [1,1])
C0220952 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
C0521116 (UMLS CUI [1,4])
C0025611 (UMLS CUI [1,5])
C0038586 (UMLS CUI [1,6])
C0038580 (UMLS CUI [1,7])
Elig.phs001197.v1.p1.11
Item
Test positive on day of screening for Meth by urine sample Medications and Substances-Evidence of current use of psychotropic medications or substances other than:
boolean
C0011008 (UMLS CUI [1,1])
C0025611 (UMLS CUI [1,2])
C2711519 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0439861 (UMLS CUI [2,2])
C3887511 (UMLS CUI [2,3])
C0521116 (UMLS CUI [2,4])
C1524063 (UMLS CUI [2,5])
C0033978 (UMLS CUI [2,6])
C1705847 (UMLS CUI [2,7])
Elig.phs001197.v1.p1.12
Item
Light use of marijuana (both groups)
boolean
C1881376 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0024808 (UMLS CUI [1,3])
Elig.phs001197.v1.p1.13
Item
Light use of alcohol (both groups)
boolean
C1881376 (UMLS CUI [1,1])
C0001948 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.14
Item
Nicotine Note: "Light use" defined by qualification for abuse but not dependence. Tobacco (cigarette) consumption is matched between groups to equalize possibly confounding effects of nicotine on cerebral blood flow, which may affect hemodynamic changes measured by fMRI.
boolean
C1704788 (UMLS CUI [1,1])
C1881376 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,3])
C0028040 (UMLS CUI [1,4])
C1704788 (UMLS CUI [2,1])
C1709790 (UMLS CUI [2,2])
C0038586 (UMLS CUI [2,3])
C1298908 (UMLS CUI [2,4])
C1709790 (UMLS CUI [2,5])
C0038580 (UMLS CUI [2,6])
C0543414 (UMLS CUI [3,1])
C0150103 (UMLS CUI [3,2])
C0441833 (UMLS CUI [3,3])
C2828389 (UMLS CUI [3,4])
C4759729 (UMLS CUI [3,5])
Elig.phs001197.v1.p1.15
Item
CNS Disease-Including:
boolean
C0007682 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.16
Item
Structural brain abnormalities (e.g., neoplasms, subarachnoid cysts)
boolean
C0851391 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.17
Item
Cerebrovascular disease
boolean
C0007820 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.18
Item
Infectious disease (e.g., abscess)
boolean
C0009450 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.19
Item
History of other neurological disease, including stroke or head trauma (defined as loss of consciousness >30 min or requiring hospitalization)
boolean
C0262926 (UMLS CUI [1,1])
C0027765 (UMLS CUI [1,2])
C0559159 (UMLS CUI [1,3])
C0018674 (UMLS CUI [1,4])
Elig.phs001197.v1.p1.20
Item
Cardiovascular Disease:
boolean
C0007222 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.21
Item
Advanced coronary artery disease, endocarditis, or other cardia disease likely to result in cerebral embolism
boolean
C0679246 (UMLS CUI [1,1])
C1956346 (UMLS CUI [1,2])
C0014118 (UMLS CUI [1,3])
C0018799 (UMLS CUI [1,4])
C1444708 (UMLS CUI [1,5])
C1274040 (UMLS CUI [1,6])
C0007780 (UMLS CUI [1,7])
Elig.phs001197.v1.p1.22
Item
Any participant that exhibits evidence of left ventricular hypertrophy will be evaluated for a history of hypertension, and will be excluded from participation if positive for hypertension
boolean
C0679646 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
C0149721 (UMLS CUI [1,3])
C0679830 (UMLS CUI [1,4])
C0262926 (UMLS CUI [1,5])
C0020538 (UMLS CUI [1,6])
C0680251 (UMLS CUI [2,1])
C0020538 (UMLS CUI [2,2])
Elig.phs001197.v1.p1.23
Item
Any participant that reports cardiac symptoms such as chest pain, presyncope and/or syncope with meth use
boolean
C0679646 (UMLS CUI [1,1])
C0741933 (UMLS CUI [1,2])
C0008031 (UMLS CUI [1,3])
C0700200 (UMLS CUI [1,4])
C0039070 (UMLS CUI [1,5])
C1524063 (UMLS CUI [1,6])
C0025611 (UMLS CUI [1,7])
Elig.phs001197.v1.p1.24
Item
Pulmonary Disease:
boolean
C0024115 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.25
Item
Significant obstructive pulmonary disease
boolean
C0750502 (UMLS CUI [1,1])
C0600260 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.26
Item
Self-reported active tuberculosis
boolean
C2700446 (UMLS CUI [1,1])
C0151332 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.27
Item
Systemic Disease:
boolean
C0442893 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.28
Item
Endocrinopathies
boolean
C0014130 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.29
Item
Renal or hepatic failure
boolean
C0035078 (UMLS CUI [1,1])
C0085605 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.30
Item
Autoimmune disease involving the CNS
boolean
C0004364 (UMLS CUI [1,1])
C1314939 (UMLS CUI [1,2])
C3714787 (UMLS CUI [1,3])
Elig.phs001197.v1.p1.31
Item
Pregnancy:
boolean
C0032961 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.32
Item
Pregnancy, possible pregnancy, or failure to indicate the use of reliable birth control precautions. Note: We administered a pregnancy test to each female participant before starting each of the testing days. Participants must agree to use an effective form of birth control throughout the study. The only acceptable methods of birth control are: 1) oral contraceptive; 2) Depo-Provera injection; 3) intrauterine device; 4) diaphragm with contraceptive jelly; 5) condom with contraceptive jelly, foam, or sponge; 6) tubal ligation or hysterectomy; 7) abstinence from heterosexual intercourse.
boolean
C0032961 (UMLS CUI [1,1])
C0425965 (UMLS CUI [1,2])
C0680095 (UMLS CUI [1,3])
C1524063 (UMLS CUI [1,4])
C0700589 (UMLS CUI [1,5])
C0032976 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0011008 (UMLS CUI [2,3])
C0039593 (UMLS CUI [2,4])
C0545082 (UMLS CUI [2,5])
C1879533 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0009905 (UMLS CUI [3,3])
C0582269 (UMLS CUI [3,4])
C0021900 (UMLS CUI [3,5])
C0042241 (UMLS CUI [3,6])
C0087145 (UMLS CUI [3,7])
C0009653 (UMLS CUI [3,8])
C0183461 (UMLS CUI [3,9])
C0020699 (UMLS CUI [3,10])
C0520483 (UMLS CUI [3,11])
C0036899 (UMLS CUI [3,12])
Elig.phs001197.v1.p1.33
Item
HIV:
boolean
C0019682 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.34
Item
HIV-seropositive will be excluded because HIV infection and the development of AIDS produce alterations in brain activity that are dependent on the stage of AIDS. Such effects on brain activity would confound the results of this study.
boolean
C0680251 (UMLS CUI [1,1])
C0019699 (UMLS CUI [1,2])
C0001175 (UMLS CUI [1,3])
Elig.phs001197.v1.p1.35
Item
Severe Hepatic Impairment:
boolean
C0948807 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Elig.phs001197.v1.p1.36
Item
Participants who have severe hepatic impairment, as assessed by blood tests and/or medical history, will be excluded from participation in order to reduce the risk of an adverse effect due to the administration of medication.
boolean
C0680251 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0948807 (UMLS CUI [1,3])
C1516048 (UMLS CUI [1,4])
C0022885 (UMLS CUI [1,5])
C0262926 (UMLS CUI [1,6])
C0392756 (UMLS CUI [1,7])
C0035647 (UMLS CUI [1,8])
C0877248 (UMLS CUI [1,9])
Elig.phs001197.v1.p1.37
Item
Only for MRI Procedures:
boolean
C0024485 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.38
Item
We excluded any participant whose body contains a ferromagnetic implanted device that might produce a safety hazard during fMRI. We followed guidelines found in the manual, Magnetic Resonance: Bioeffects, Safety, and Patient Management, supplemented by the current information published on the International MR Safety Website: http://www.mrisafety.com/safety_info.asp
boolean
C0680251 (UMLS CUI [1,1])
C3693688 (UMLS CUI [1,2])
C2911688 (UMLS CUI [1,3])
C0347984 (UMLS CUI [1,4])
C0376335 (UMLS CUI [1,5])
Elig.phs001197.v1.p1.39
Item
Language:
boolean
C0023008 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.40
Item
Lack of fluency in English. If a participant is not a fluent English speaker, the language barrier would interfere with performance of psychological tests and completing questionnaires used in the study. The consent form, all questionnaires and instructions are given in English.
boolean
C0332268 (UMLS CUI [1,1])
C0564215 (UMLS CUI [1,2])
C0376245 (UMLS CUI [1,3])
C0237167 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0597198 (UMLS CUI [2,3])
C0033905 (UMLS CUI [2,4])
C0034394 (UMLS CUI [2,5])
C0034394 (UMLS CUI [3,1])
C0021430 (UMLS CUI [3,2])
C1442085 (UMLS CUI [3,3])
C0376245 (UMLS CUI [3,4])
Elig.phs001197.v1.p1.41
Item
Neurological:
boolean
C0746866 (UMLS CUI [1,1])
Elig.phs001197.v1.p1.42
Item
Neurological status that is not within normal limits as determined by a physician and as indicated in self-reports.
boolean
C0746866 (UMLS CUI [1,1])
C0205161 (UMLS CUI [1,2])
C0521095 (UMLS CUI [1,3])
C0031831 (UMLS CUI [1,4])
C2700446 (UMLS CUI [1,5])
Elig.phs001197.v1.p1.43
Item
Radiation Exposure: Participated in any other research study involving exposure to ionizing radiation in the past year, relating to study visit date, if the total cumulative exposure from the past research studies and the current research study exceeded the limits described by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must have remained below 5 rems, and the cumulated dose to all other organs must have remained below 15 rems.
boolean
C0015333 (UMLS CUI [1,1])
C0679823 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0008972 (UMLS CUI [1,4])
C0479513 (UMLS CUI [1,5])
C4086728 (UMLS CUI [1,6])
C2986497 (UMLS CUI [1,7])
C0015333 (UMLS CUI [1,8])
C3846158 (UMLS CUI [1,9])
C0150269 (UMLS CUI [1,10])
C0678257 (UMLS CUI [1,11])
C0041714 (UMLS CUI [1,12])
C2986497 (UMLS CUI [2,1])
C0370231 (UMLS CUI [2,2])
C1328851 (UMLS CUI [2,3])
C0023317 (UMLS CUI [2,4])
C0018067 (UMLS CUI [2,5])
C0439092 (UMLS CUI [2,6])
C3846158 (UMLS CUI [2,7])
C2986497 (UMLS CUI [3,1])
C0205394 (UMLS CUI [3,2])
C0178784 (UMLS CUI [3,3])
C0439092 (UMLS CUI [3,4])
C3846158 (UMLS CUI [3,5])
Elig.phs001197.v1.p1.44
Item
Radiation Exposure: Participated in any other research study involving exposure to ionizing radiation in the past year, relating to study visit date, if the total cumulative exposure from the past research studies and the current research study exceeded the limits described by the FDA in 21 CFR 361.1. Specifically, the total cumulated dose to the whole body, active blood-forming organs, lens of the eye, and gonads must have remained below 5 rems, and the cumulated dose to all other organs must have remained below 15 rems.
boolean
C0015333 (UMLS CUI [1,1])
C0679823 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0008972 (UMLS CUI [1,4])
C0479513 (UMLS CUI [1,5])
C2986497 (UMLS CUI [1,6])
C0015333 (UMLS CUI [1,7])
C3846158 (UMLS CUI [1,8])
C0150269 (UMLS CUI [1,9])
C0678257 (UMLS CUI [1,10])
C0041714 (UMLS CUI [1,11])
C2986497 (UMLS CUI [2,1])
C0370231 (UMLS CUI [2,2])
C1328851 (UMLS CUI [2,3])
C0023317 (UMLS CUI [2,4])
C0439092 (UMLS CUI [2,5])
C3846158 (UMLS CUI [2,6])
C2986497 (UMLS CUI [3,1])
C0205394 (UMLS CUI [3,2])
C0178784 (UMLS CUI [3,3])
C0439092 (UMLS CUI [3,4])
C3846158 (UMLS CUI [3,5])
Back to the top of the page 

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial